<div class="box02 st01"> <ul class="list02"> <li>STADA CIS is a Russian holding company forming a part of STADA Arzneimittel AG international group that amalgamated two leading companies of domestic pharmaceutical market, namely NIZHPHARM and MAKIZ-PHARMA.</li> <li>STADA CIS holding activities are aimed at ultimate revelation and satisfaction of needs related to gain in health of the customers who prefer modern and efficient medications.</li> <li>STADA CIS holding company features a diversified organization structure that embraces pharmaceutical companies which activities are associated with three principal directions: development, production and promotion of pharmaceutical products.</li> </ul> <p class="txt03">STADA PharmDevelopment, R&D is a STADA CIS holding subdivision that on the basis of its research laboratories works on high-technology medications development, commissioning and introduction to the market being an active participant of a program intended for imported drugs replacement by high-quality domestic analogs. In addition to development of generic medications specialists of this holding company together with the leading research-and-development centers of Russia and CIS countries are occupied with clinical trials and innovative medicinal products development in the most important therapeutic areas of medicine.</p> <p class="txt03">Production facilities of NIZHPHARM (Nizhny Novgorod), MAKIZ-PHARMA (Moscow city), SCOPINPHARM (Ryazan region) with the total production capacity of:</p> <ul class="list02"> <li>Suppositories: 360, 000, 000 pieces</li> <li>Ointments, creams, gels: 81, 120, 000 pieces</li> <li>Tablets: 1 831, 900, 000 pieces</li> <li>Capsules: 208, 100, 000 pieces</li> <li>Solutions: 2, 160, 000 pieces</li> </ul> <p class="txt03">One of the best quality management systems adopted in the leading Russian manufacturers has been created and now is successfully employed by manufacturing companies of STADA CIS holding. All production sites of the holding comply with the GMP international standards. Quality and environment management system is certified in accordance with ISO 9001:2008 and ISO 14001:2004 international standards.</p> <p class="txt03">STADA Marketing, STADA Ukraine, STADA Central Asia, STADA Azerbaidjan and STADA Armenia are the companies responsible for marketing policy implementation for the purpose of the most perspective products supporting within STADA CIS’s key markets of Russia, Ukraine, Central Asia (Kazakhstan, Tajikistan, Kyrgyzstan, Uzbekistan) and Transcaucasia countries (Armenia, Azerbaijan).</p> <p class="txt03">Currently the product portfolio of STADA CIS holding company includes more than 100 medications of various АТС-classes and pharmaceutical forms. While elaborating the portfolio STADA CIS places a priority on pharmaceuticals used in gastroenterology, neurology, gynecology, cardiology, urology as well as those administrated while musculoskeletal system disorders and antiviral medications.</p> <p class="txt03">Following the policy of focusing on development of modern drugs with unique properties needed in the most important and worthwhile medicine areas and continuously investing in the quality management system and production technologies enhancement, STADA CIS holding company seeks to achieve the first-priority strategic goal, namely provision of customers with high-quality and efficient pharmaceutical products at acceptable prices.</p> </div>
소스입니다. Ctrl+C를 눌러 클립보드로 복사하세요

닫기